A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in
participants with locally advanced or metastatic Breast Cancer will be investigated to assess
the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose
(MAD) for MTD is not reached of GNC-035.